Is there a generic version of adagrasib? how about the price

The original drug Adagrasib (Adagrasib) is currently marketed and sold in many overseas countries. It is a small molecule inhibitor of KRAS G12C mutant protein and is used to treat adult non-small cell lung cancer (NSCLC). According to the latest overseas news, generic drugs of adagrasibu are currently being produced and sold, and their pharmaceutical ingredients are basically the same as those of the original drug. There may be slight differences in production specifications and prices. This is the world's first generic drug of adagrasibu, and its price may be only one-tenth of the original drug.

Adagrasib is an oral, small molecule inhibitor of the product of the KRAS gene, a mutated oncogene commonly found in many forms of cancer, most commonly in non-small cell lung cancer (NSCLC). The KRAS (Kristen rat sarcoma viral oncogene homolog) G12C mutation produces a constitutively active protein receptor (a member of the RAS GTPase family) that stimulates excessive cell growth. Adagarasib binds to the abnormal receptor and locks it into an inactive conformation, thereby inhibiting cell growth and proliferation in tumor cell lines and experimental tumor models harboring the KRAS G12C mutation. In a large open-label trial, adagrasib was found to induce objective responses in 43% of patients with refractory NSCLC harboring KRAS G12C mutations and was well tolerated.

Since the original drug of adagrasibu is not on the market in China, domestic patients cannot yet purchase this drug. The US version of the original adagrasibu drug currently sold overseas costs hundreds of thousands of yuan. The high price will increase the financial burden of some families. However, for the newly launched generic drug of adagrasibu, Specifications200mg*90 tablets are priced at more than 4,000 yuan per box (the price may fluctuate due to exchange rates).